Kornimate/medical-research-clean huggingface dataset:
comparison of a speech-language assessment tool for pragmatic and discourse skills in schizophrenia spectrum disorders

Conditions: Psychotic Disorders

Summary: the scientific literature has largely objectified language disorders in schizophrenia. and more precisely, the impairment of pragmatic and discursive language skills. currently, there is no standardized language assessment tool specific to these patients. the aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .

the scientific literature has largely objectified language disorders in schizophrenia. and more precisely, the impairment of pragmatic and discursive language skills. currently, there is no standardized language assessment tool specific to these patients. the aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia. to do so, patients will have to pass six tests: three tests of the new tool and three corresponding gold standard tests. the first two tests will assess pragmatic skills by means of a semi-directed interview. the next two tests will assess discourse skills through two image description tasks. finally, the last two tests will evaluate narrative skills through the oral restitution of two heard texts. the main objective is to compare the performance of schizophrenic patients detected in the pathological zone with the scales of the new tool versus the gold standard scales. the secondary objective is to determine which skills are most affected by comparing patients' scores in pragmatic skills versus those in discourse skills. this tool would allow to precisely objectify language disorders and to optimize the multidisciplinary diagnosis and care of patients suffering from schizophrenia.

Eligibility criteria:
inclusion criteria: * male or female between the ages of 18 and 60 * patient with a diagnosis of schizophrenic spectrum disorder and other psychotic disorders meeting dsm v criteria * patient who has been clinically and treatment stable for at least three months * patient who can read and write french * patient who is a beneficiary of a social security plan or similar * patient with ability to sign free and informed consent exclusion criteria: * - patient hospitalized under restraint * patient under guardianship * patient who has stopped taking his or her treatment * patient who had a change in treatment in the period of less than three months prior to the pass * patient with a worsening of the disease in the three months prior to the inclusion visit
clinical triage and treatment of atypical glandular cells (agc) detected in screening

Conditions: Uterine Cervical Cancer

Summary: the risk of cervical cancer after diagnosis with atypical glandular cells (agc) detected by screening is elevated for 15 years after discovery. the current recommendation is that when agc is detected during screening, referel is made to a gynecologist for colposcopy with biopsy within 3 months after the index test. repeated tests should be done after one year and after two years and if these are negative, the woman can return to routine screening. given the increased risk of cancer associated with agc a new evaluation of the optimal follow-up and treatment of agc, which is detected during screening, is carried out. in this randomized study, women with agc will be randomized to routine treatment according to current guidelines or to conization. the aim of the study is to determine which of the two treatments is most effective.

evidence from a nationwide cohort study demonstrated that the risk of cervical cancer following a diagnosis of agc detected in screening was elevated for 15 years, particularly the risk of adenocarcinoma. furthermore, the study suggested that compared to high-grade squamous intraepithelial lesion (hsil) management, the management of agc has been suboptimal in sweden (wang et al., bmj 2016). a study conducted in the greater metropolitan region of stockholm showed that the ppv for high grade lesions was 60% for human papillomavirus (hpv) positive agc detected in screening (norman et al., bmj open, 2017). the new guidelines for cervical cancer prevention were adopted in january of 2017 nationally and in december 2017 in county of stockholm and outline a clinical management strategy for agc. the recommendation is that agc detected in screening, regardless of hpv status, should be referred to a gynecologist for colposcopy with biopsy within 3 months of the index test. for women over the age of 40, an ultrasound and endometrial biopsy is also recommended. repeat tests should be done at one year and two years, if these are negative then the woman can return to routine screening. the elevated risk for high grade lesions and cancer associated with agc, coupled with the reality that cervical cancer incidence has increased in sweden, begs a new evaluation of the optimal clinical management and treatment of agc detected in screening. women will be randomized to routine management according to the new guidelines or to an alternative management.

Eligibility criteria:
inclusion criteria: * give informed consent * women diagnosed with agc (atypical glandular cells, m69720) and hpv 16/18 positive, detected in cervical screening. exclusion criteria: * do not give informed consent * hpv negative or none-hpv16/18 positive

Keywords: cervical cancer, atypical glandular cells
evaluation of rtvue in corneal measurement

Conditions: Normal Cornea; Post Laser Refractive Surgery; Cornea Pathology; Cataract Surgery

Summary: the purpose of this study is to evaluate rtvue measurement of the cornea in various ocular conditions to include normal, pathology, post refractive surgery and cataract.


Eligibility criteria:
inclusion criteria: normal cornea: * 18 years of age or older * no corneal pathology * no prior ocular surgery and no prior laser refractive surgery post laser refractive surgery: * 18 years of age or older * no corneal pathology * no prior ocular surgery except laser refractive surgery * at least 1 week post laser refractive surgery without complication corneal pathology: * 18 years of age or older * clinical diagnosis of one or more type of corneal pathologies, including corneal scar and keratoconus, etc., excluding eyes in which corneal power measurement are not clinically relevant (e.g., eyes requiring corneal transplant) * no prior laser refractive surgery cataract surgery: * 18 years of age or older * no corneal pathology * no prior ocular surgery, no prior laser refractive surgery, and no prior cataract surgery * post surgery visit shall only include eyes without complication
radiofrequency fields in neonatology: exposure and impact on the nervous system

Conditions: Preterm Newborn

Summary: previously, the investigators showed that preterm newborns are exposed chronically to very low radiofrequency levels in average while hospitalized in nicus. most of the infants were nevertheless frequently exposed to transient values above 1 v/m. the investigators also showed that an increase in rf exposure is likely to alter the activity of some neurophysiological functions and their regulatory systems in preterm newborns. the investigators hypothesize that above results are extremely specific to the location of the previous study and may be different in other nicu environments. this study will aim at quantifying rf levels to which preterm newborns are exposed during their stay in several nicus spread across the french territory, and assessing its impact on the central and peripheral nervous systems. the first step of this study will be to quantify the precise, continuous and individual levels of daily rf exposure to which each recruited neonate is subjected during his stay in the different nicus from birth to 1 week postnatal life. infants' clinical data (medical history, nutrition, morphology...) will also be continually monitored. at 1 week postnatal life, the investigators will investigate cerebral activity (eeg) and autonomic nervous system activity (ecg, heart rate variability). the impact of rf will be evaluated by analyses of the relationship between exposure levels and the various parameters extracted from the neurophysiological investigation phase.


Eligibility criteria:
inclusion criteria: * preterm newborns born between 26-34 weeks of gestational age exclusion criteria: * infants infected, * suffering from neurological disorders, * serious heart, respiratory, digestive or metabolic diseases; * infants born from mothers aged less than 18 years old or deprived of their parental rights

Keywords: preterm newborn radiofrequencies central and peripheral nervous systems
metformin as adjuvant therapy in obese knee osteoarthritis patients

Conditions: Knee Osteoarthritis

Summary: this study aims to evaluate the possible efficacy and safety of addition of metformin to celecoxib in patients with knee osteoarthritis.

metformin is a safe, well-tolerated oral biguanide widely used as first-line therapy for type 2 diabetes for over 50 years. in addition to its glucose-lowering effects, metformin modulates inflammatory and metabolic factors resulting in weight loss and reduced inflammation and plasma lipids. data from animal studies suggest that metformin could limit oa development and progression, possibly through activating ampk. retrospective cohort study of participants with oa and type 2 diabetes reported that patients receiving a combination of cyclooxygenase-2 inhibitors and metformin therapy had a lower risk of joint replacement than those receiving cyclooxygenase-2 inhibitors alone . these findings shed light on possible therapeutic potential of metformin in treatment of oa.

Eligibility criteria:
inclusion criteria: * patients have symptomatic and radiological evidence of oa in one or both knee joints. * age ≥ 45 years. * both obese male and female will be included (bmi ≥ 30 kg/m²). exclusion criteria: * patients with inflammatory rheumatic diseases, crystal deposition arthritis or infection-induced oa. * patient with hypertension or diabetes mellitus. * patient with hepatic or renal impairment. * patients who have active peptic ulcer. * patients with positive malignancy. * steroid injection into the affected knee joint within 3 months of recruitment for the study. * pregnant or lactating female patients.

Keywords: metformin knee osteoarthritis
effect of nefazodone on relapse in females with cocaine abuse - 10

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to determine the effect of nefazodone on relapse to cocaine use in depressed and non-depressed females with cocaine abuse/dependence.

the purpose of this study is to determine the effect of nefazodone on relapse to cocaine in women and if a greater effect will be seen in the dependent condition. a relapse and coping skills questionnaire will be utilized to determine the various factors important to the relapse process.

Eligibility criteria:
inclusion criteria: female, ages 18-55, cocaine abuse/dependence, use of cocaine 7 days of the last 30 days or of the 30 days prior to current abstinence, less than 90 days current abstinence, at least an 8th grade education. exclusion criteria: unstable medical conditions; current use of hismanal, seldane, or propulsid; dx of mr, obs, bipolar, schizophrenia.

Keywords: cocaine dependence
evaluation of an entrepreneurship program for american-indian youth

Conditions: Depressive Symptoms; Substance Use

Summary: this study will use a randomized controlled design to evaluate whether a youth entrepreneurship/life-skills intervention for reservation-based american indian adolescents (ages 13-15) improves psychosocial, behavioral health, educational, and economic outcomes from baseline for up to 3 years follow-up as compared to a recreational sports league control condition.

intervention activities will be held over a 3 night/4 day residential camp and 6 weekend workshops during the academic year. the control condition will consist of a recreational sports league held on 3 saturdays, also during the academic year.

Eligibility criteria:
inclusion criteria: * american indian ethnicity and primary residence within the fort apache indian reservation. * participants must be 13-15 years old, enrolled as a student at one of the participating high schools, and must have parent/guardian consent for participation in the study. exclusion criteria: * youth that are currently enrolled in foster care will not be eligible to participate in the study. * those unable to participate in any of the evaluation assessments or intervention components will also be excluded.

Keywords: american indian adolescents entrepreneurship paraprofessional life skills
smart heart trial: structured lifestyle intervention for overweight and obese youth with operated heart defects

Conditions: Congenital Heart Disease; Pediatric Obesity

Summary: this study is to assess whether a lifestyle intervention with diet, exercise and counselling in young patients will have a positive influence on their weight and overall well-being. this study will enrol patients between the ages of 7 to 17 years of age, who have congenital heart disease, and have been identified being overweight or obese. a total of 40 individuals will participate in this study. the study duration will last for 1 year.


Eligibility criteria:
inclusion criteria: * overweight or obese (bmi\> 85%) patients * between 7-17 years of age * operated or non-operated congenital heart disease * reside in southwestern ontario exclusion criteria: * inability to comply with research testing or intervention components due to mental and/or physical disabilities, medications or comorbidities affecting weight or metabolic condition * involvement in any concurrent lifestyle intervention program

Keywords: congenital heart disease smart mobile technology children adolescents lifestyle counselling nutrition physical activity
a study of nystatin in the prevention of fungal infections of the mouth in patients with aids or aids-related syndromes

Conditions: Candidiasis, Oral; HIV Infections

Summary: to determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prophylaxis of oral candidiasis in patients with aids or aids related syndromes (group iii or iv, cdc classification)


Eligibility criteria:
inclusion criteria concurrent medication: allowed: * experimental drugs (ind drugs) which are targeted specifically against the aids virus or which stimulate the immune system. * systemic or oral antibiotics. patients must have aids or aids-related syndromes (hiv infection: * group iii or iv, cdc classification) and not have been treated for oral candidiasis during the past year. * patients can be entered into the study who have: * other oral lesions due to kaposi's sarcoma, herpes zoster, and herpes simplex. * a positive or negative oral culture for candida. * must be able to follow instructions regarding the use of a pastille. exclusion criteria co-existing condition: patients with the following are excluded: * oral lesions diagnostic of oral candidiasis or systemic candidiasis. * suspected or proven candidal esophagitis. patients with the following are excluded: * oral lesions diagnostic of oral candidiasis or systemic candidiasis. * receiving any effective antifungal agent orally or intravenously within 72 hours of study entry. * not expected to survive for at least 6 months. * unable to voluntarily maintain a pastille in the buccal cavity for approximately 20 minutes twice a day. * known hypersensitivity to nystatin. * suspected or proven candidal esophagitis. prior medication: excluded within 72 hours of study entry: * any oral or intravenous antifungal agent.

Keywords: nystatin aids-related opportunistic infections acquired immunodeficiency syndrome aids-related complex candidiasis, oral
treatment of delirium in the elderly with donepezil: a double-blind, randomized, placebo-controlled clinical trial

Conditions: Elderly; Delirium of Unknown (Axis III) Etiology; Intensive Care (ICU) Myopathy

Summary: nowadays features for the diagnosis of delirium are: 1. disturbance of consciousness (i.e. reduced clarity of environment awareness) with reduced ability to focus, sustain or shift attention; 2. a change in cognition (such as memory deficit, disorientation, language disturbance) or the development of a perceptual disturbance that is not better accounted for by a pre-existing or evolving dementia; 3. the disturbance develops over a short period of time (usually hours to days) and its severity fluctuates during the course of the day; 4. there is evidence from the history, physical examination, or laboratory findings that the disorder is caused by the direct physiological consequences of a general medical condition, substance intoxication or substance withdrawal. treatment of underlying clinical disease is important to remit the delirium. however, these procedures alone are not enough to remit the delirium early and to prevent sequels. there is a need for a specific and faster strategy to treat the delirium. the investigators want to test the hypothesis that an anticholinesterase inhibitor (donepezil) can reduce the duration of the delirium.


Eligibility criteria:
inclusion criteria: * over 60 year old * delirium according to the cam-icu (confusion assessment method for intensive care unit) * informed consent (legal representatives) exclusion criteria: * unable to swallow pills * previous allergy to donepezil * atrioventricular block of 2nd and 3nd degree
load vs levofloxacine concomitant

Conditions: Helicobacter Pylori Infection

Summary: comparison efficacy of two weeks therapy with doxycycline,levofloxacine,tinadizole versus levofloxacine,tinadizole,amocillin on eradication of helicobacter pylori in syrian population.


Eligibility criteria:
inclusion criteria: * patients are aged greater than 18 years old who have h. pylori infection diagnosed by any of following three methods: * positive rapid urease test (clotest). * histologic evidence of h. pylori by modified giemsa staining. * positive 13c-urea breath test. without prior eradication therapy and are willing to receive therapy. exclusion criteria: * children and teenagers aged less than 18 years. * previous eradication treatment for h. pylori. * patients who took any drug, which could influence the study results such as proton pump inhibitor, h2 blocker, mucosal protective agent and antibiotics. * history of gastrectomy. * gastric malignancy, including adenocarcinoma and lymphoma, * previous allergic reaction to antibiotics (amoxicillin, tinadizole, * doxycycline,bismuth subsalicylate,) and prompt pump inhibitors (es- omeprazole). * contraindication to treatment drugs. * pregnant or lactating women. * severe concurrent disease. * liver cirrhosis.

Keywords: doxycycline load regimen helicobacter pylori levofloxacine tinadizole
switching medication and augmentation strategies for ssri-resistant adolescent depression（smart-i)

Conditions: Major Depressive Disorder (MDD)

Summary: this project aims to investigate the effectiveness of existing common antidepressants in adolescents with mdd who did not respond to their first treatment.

this project aims to investigate the effectiveness of existing common antidepressants in adolescents with mdd who did not respond to their first treatment. adolescents ages 12 to 17, currently taking a prescribed selective serotonin reuptake inhibitor (ssri) at least 8 weeks and still experiencing depression, participate in a 8-week randomized treatment study that includes one of three conditions: (1) switching to sertraline , (2) switching to duloxetine , (3) augmentation of their original ssri with aripiprazole.

Eligibility criteria:
inclusion criteria: 1. aged 12-17; 2. as assessed by k-sads-pl, it meets the dsm-5 criteria for mdd; 3. cdrs-r≥45; 4. cgi-s≥4; 5. failed to respond to an initial ssri trial: the trial at least 8 weeks, with the last of which were at a dosage of at least 40 mg per day of fluoxetine or its equivalent. exclusion criteria: 1. current or lifetime diagnosis of bipolar disorder, schizophrenia, autism, attention-deficit/hyperactivity disorder or obsessive-compulsive disorder or psychosis not otherwise specified; 2. mdd with psychotic symptoms; 3. ymrs\>13; 4. current or lifetime diagnosis of serious neurologic diseases such as epilepsy, brain trauma or other serious physical illnesses; 5. failure to respond adequately to two or more antidepressant treatment trials of recommended dose and length (at least 8 weeks, with the last 4 of which were at a dosage of at least 40 mg per day of fluoxetine or its equivalent); 6. history of clear-cut intolerability of, or lack of effect with, an adequate trial of sertraline, agomelatine, or aripiprazole; 7. current depressive episode with clear suicidal plans or behaviors; 8. received modified electroconvulsive therapy within 3 months; 9. taking any medicine that contraindicates in combination with or interferes with the efficacy of the treatment; 10. substance abuse or dependence; 11. female patients with pregnancy.

Keywords: adolescent ssri depression
exploring psychometric properties of a new version of the 6mwt in the acute stroke population

Conditions: Acute Stroke

Summary: the purpose of this study is to assess inter- and intra-rater reliability of the 6mwt in people with acute stroke who require various levels of assistance with walking.


Eligibility criteria:
inclusion criteria: * at least 18 years old * primary diagnosis of an acute or hemorrhagic stroke * admitted into the acute or acute rehab setting and is appropriate for physical therapy services. * can ambulate with 1 person assistance and a device as needed, with no more than maximal assistance required. the patient must be able to independently advance the lower extremity forward, but can receive maximal assistance for blocking, bracing or postural control during ambulation. * can stand and/or ambulate for at least 6 minutes exclusion criteria: * hemodynamically unstable * unstable medical co-morbidities such as: active bleeding, recurring seizures, uncontrolled hypertension (permissive htn orders ok) * patients with bilateral acute stroke * patients who are unable to follow 1 step commands as determined by the screening physiatrist * orthopedic co-morbidities that place a weight-bearing restriction on the lower extremities such as acute fracture, joint replacement, or other musculoskeletal injury * any other condition that would limit a patient's ability to remain in a standing position with assistance for 6 minutes at a time.